#Fda-Approval

2 stories

Clinical Trials April 5, 2026 · View digest

FDA Approves Orforglipron: First GLP-1 Pill Without Food or Water Restrictions

Orforglipron (Foundayo) is the first GLP-1 pill that can be taken at any time without food or water restrictions, a major differentiator from oral semaglutide which requires morning dosing on an empty stomach.

Clinical Trials April 1, 2026 · View digest

Orforglipron FDA Decision Expected in April 2026

Eli Lilly's oral GLP-1 drug orforglipron is among the most consequential FDA decisions in Q2 2026. Analysts expect it to help Lilly's tirzepatide franchise exceed $100 billion in peak revenue.